Summaries & Associations of Study Results
TR-356 Furosemide
Target Organs and Levels of Evidence
NTP Technical Report Number 356
Produced from Chemtrack Database 09/19/01
CHEMICAL/ CAS NUMBER | PEER REVIEW DATE | PRIMARY USES | ROUTE/EXPOSURE LEVELS | STUDY LABORATORY |
---|---|---|---|---|
FUROSEMIDE 54-31-9 |
04/18/88 | DIURETIC IN THE TREATMENT OF EDEMA AND HYPERTENSION. DIURETIC IN VETERINARY MEDICINE. (TDB) | Dosed-Feed R: 0,350,700, M: 0,700,1400 PPM/50 PER GROUP | SRI International |
LEVELS OF EVIDENCE OF CARCINOGENICITY--ORGAN/TISSUE (NEOPLASM): | ||||
MR: EQUIVOCAL EVIDENCE | KIDNEY TUBULAR CELL: ADENOMA 1/50 3/50 1/50 OR CARCINOMA 0/50 1/50 1/50 COMBINED 1/50 4/50 2/50 | |||
BRAIN: MENINGIOMA 0/50 3/50 0/50 | ||||
NON-NEOPLASTIC LESIONS: | KIDNEY: INCREASED SEVERITY OF NEPHROPATHY | |||
FR: NO EVIDENCE | ||||
MM: NO EVIDENCE | ||||
NON-NEOPLASTIC LESIONS: | KIDNEY: INCREASED SEVERITY OF NEPHROPATHY | |||
FM: SOME EVIDENCE | MAMMARY GLAND: ADENOCARCINOMA 0/50 2/50 5/48 | |||
NON-NEOPLASTIC LESIONS: | KIDNEY: INCREASED SEVERITY OF NEPHROPATHY |
Web page last updated on February 10, 2006